CAPR
Price
$6.82
Change
+$0.05 (+0.74%)
Updated
Mar 28, 1:57 PM EST
42 days until earnings call
VYNE
Price
$3.01
Change
+$0.05 (+1.69%)
Updated
Mar 28, 2:31 PM EST
Ad is loading...

CAPR vs VYNE ᐉ Comparison: Which is Better to Invest?

Header iconCAPR vs VYNE Comparison
Open Charts CAPR vs VYNEBanner chart's image
Capricor Therapeutics
Price$6.82
Change+$0.05 (+0.74%)
Volume$900
CapitalizationN/A
VYNE Therapeutics
Price$3.01
Change+$0.05 (+1.69%)
Volume$329
CapitalizationN/A
View a ticker or compare two or three
CAPR vs VYNE Comparison Chart

Loading...

CAPRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VYNEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CAPR vs. VYNE commentary
Mar 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAPR is a StrongBuy and VYNE is a Hold.

COMPARISON
Comparison
Mar 28, 2024
Stock price -- (CAPR: $6.76 vs. VYNE: $2.97)
Brand notoriety: CAPR and VYNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAPR: 139% vs. VYNE: 273%
Market capitalization -- CAPR: $212.26M vs. VYNE: $41.87M
CAPR [@Biotechnology] is valued at $212.26M. VYNE’s [@Biotechnology] market capitalization is $41.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $576.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.64B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAPR’s FA Score shows that 0 FA rating(s) are green whileVYNE’s FA Score has 0 green FA rating(s).

  • CAPR’s FA Score: 0 green, 5 red.
  • VYNE’s FA Score: 0 green, 5 red.
According to our system of comparison, VYNE is a better buy in the long-term than CAPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAPR’s TA Score shows that 7 TA indicator(s) are bullish while VYNE’s TA Score has 6 bullish TA indicator(s).

  • CAPR’s TA Score: 7 bullish, 4 bearish.
  • VYNE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CAPR is a better buy in the short-term than VYNE.

Price Growth

CAPR (@Biotechnology) experienced а -1.31% price change this week, while VYNE (@Biotechnology) price change was +36.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.84%. For the same industry, the average monthly price growth was +4.95%, and the average quarterly price growth was +89.18%.

Reported Earning Dates

CAPR is expected to report earnings on May 09, 2024.

VYNE is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (+4.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CAPR with price predictions.
OPEN
A.I.dvisor published
a Summary for VYNE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CAPR($212M) has a higher market cap than VYNE($41.9M). CAPR YTD gains are higher at: 38.241 vs. VYNE (27.468). CAPR has higher annual earnings (EBITDA): -23.01M vs. VYNE (-29.26M). VYNE has more cash in the bank: 93.3M vs. CAPR (39.5M). VYNE has less debt than CAPR: VYNE (214K) vs CAPR (2.24M). CAPR has higher revenues than VYNE: CAPR (25.2M) vs VYNE (424K).
CAPRVYNECAPR / VYNE
Capitalization212M41.9M506%
EBITDA-23.01M-29.26M79%
Gain YTD38.24127.468139%
P/E RatioN/A2.71-
Revenue25.2M424K5,943%
Total Cash39.5M93.3M42%
Total Debt2.24M214K1,045%
FUNDAMENTALS RATINGS
CAPR vs VYNE: Fundamental Ratings
CAPR
VYNE
OUTLOOK RATING
1..100
2625
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
42
Fair valued
PROFIT vs RISK RATING
1..100
66100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3545
P/E GROWTH RATING
1..100
10076
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYNE's Valuation (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for CAPR (80) in the Biotechnology industry. This means that VYNE’s stock grew somewhat faster than CAPR’s over the last 12 months.

CAPR's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for VYNE (100) in the Pharmaceuticals Major industry. This means that CAPR’s stock grew somewhat faster than VYNE’s over the last 12 months.

VYNE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as CAPR (99) in the Biotechnology industry. This means that VYNE’s stock grew similarly to CAPR’s over the last 12 months.

CAPR's Price Growth Rating (35) in the Biotechnology industry is in the same range as VYNE (45) in the Pharmaceuticals Major industry. This means that CAPR’s stock grew similarly to VYNE’s over the last 12 months.

VYNE's P/E Growth Rating (76) in the Pharmaceuticals Major industry is in the same range as CAPR (100) in the Biotechnology industry. This means that VYNE’s stock grew similarly to CAPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CAPRVYNE
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 29 days ago
86%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Ad is loading...
CAPRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VYNEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRTA25.130.38
+1.54%
Prothena Corp
SMAR38.400.30
+0.79%
Smartsheet
INFY17.790.04
+0.23%
Infosys Limited
HRTG10.50-0.27
-2.51%
Heritage Insurance Holdings
CREX3.75-0.17
-4.34%
Creative Realities

CAPR and

Correlation & Price change

A.I.dvisor tells us that CAPR and SRPT have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CAPR and SRPT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAPR
1D Price
Change %
CAPR100%
+7.13%
SRPT - CAPR
32%
Poorly correlated
+1.53%
MDGL - CAPR
30%
Poorly correlated
+4.52%
FATE - CAPR
30%
Poorly correlated
+7.00%
EIGR - CAPR
29%
Poorly correlated
-7.18%
SLNO - CAPR
28%
Poorly correlated
-0.81%
More

VYNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYNE has been loosely correlated with FATE. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if VYNE jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYNE
1D Price
Change %
VYNE100%
+4.95%
FATE - VYNE
33%
Loosely correlated
+7.00%
ZLAB - VYNE
31%
Poorly correlated
+1.44%
DSGN - VYNE
31%
Poorly correlated
+9.24%
EFTR - VYNE
28%
Poorly correlated
+4.18%
CLSD - VYNE
28%
Poorly correlated
-1.18%
More